GLP-1 therapies have undergone a remarkable transformation in recent years. Once considered a niche treatment for type 2 diabetes, GLP-1s have since gained rapid public attention driven by their effectiveness in weight management. Today, adoption is accelerating globally at pace. Surveys suggest that around one in eight adults in the US has already used a GLP-1 drug, while in the UK it’s estimated that 1.6 million people have turned to these therapies for weight management in the past year alone.
This real-world uptake is mirrored in clinical research, as scientific interest in understanding the full therapeutic potential grows. Phesi’s recent analysis found obesity has become the sixth most studied disease area globally – an increase driven largely by GLP-1 innovation. While this investment brings opportunity, it also introduces new complexities for trial sponsors navigating a crowded and competitive landscape.
GLP-1s moving towards platform therapy
The use of GLP-1 receptor agonists for diabetes treatment represents one of the most significant success stories in modern drug development. Initially developed to regulate blood glucose in diabetes patients, they have since redefined the treatment landscape for obesity.
However, GLP-1s true potential lies beyond weight management alone. The underlying biology of GLP-1s, impacting insulin secretion, inflammation and cardiovascular function, makes them promising candidates to influence a wide range of disease pathways. As a result, GLP-1s are being considered not just as therapies for individual conditions but as ‘platform therapies’ with applications across multiple therapeutic areas.
Read the article in full here.